Cargando…

Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study

AIMS/HYPOTHESIS: The renal and cardiovascular protective effects of angiotensin receptor blocker (ARB) remain controversial in type 2 diabetic patients treated with a contemporary regimen including an angiotensin converting enzyme inhibitor (ACEI). METHODS: We examined the effects of olmesartan, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imai, E., Chan, J. C. N., Ito, S., Yamasaki, T., Kobayashi, F., Haneda, M., Makino, H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3210358/ https://www.ncbi.nlm.nih.gov/pubmed/21993710 http://dx.doi.org/10.1007/s00125-011-2325-z

Ejemplares similares

Effects of blood pressure on renal and cardiovascular outcomes in Asian patients with type 2 diabetes and overt nephropathy: a post hoc analysis (ORIENT-blood pressure)
por: Imai, Enyu, et al.
Publicado: (2016)

Effects of dual blockade of the renin–angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT–Hypertension)
por: Imai, Enyu, et al.
Publicado: (2013)

Clinical Value of Complement Activation Biomarkers in Overt Diabetic Nephropathy
por: Pelletier, Karyne, et al.
Publicado: (2019)

Lipid Abnormalities in Type 2 Diabetes Mellitus Patients with Overt Nephropathy
por: Palazhy, Sabitha, et al.
Publicado: (2017)

Association Between Remission of Macroalbuminuria and Preservation of Renal Function in Patients With Type 2 Diabetes With Overt Proteinuria
por: Yokoyama, Hiroki, et al.
Publicado: (2013)

Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events in patients with diabetes and overt nephropathy: a meta-analysis of randomised controlled trials
por: Shunan, Fan, et al.
Publicado: (2018)

A1C Variability Predicts Incident Cardiovascular Events, Microalbuminuria, and Overt Diabetic Nephropathy in Patients With Type 1 Diabetes
por: Wadén, Johan, et al.
Publicado: (2009)

Long-term effect of modification of dietary protein intake on the progression of diabetic nephropathy: a randomised controlled trial
por: Koya, D., et al.
Publicado: (2009)

Safety and efficacy of skin patches containing loxoprofen sodium in diabetic patients with overt nephropathy
por: Araki, Hisazumi, et al.
Publicado: (2013)

Role of IGFBP7 in Diabetic Nephropathy: TGF-β1 Induces IGFBP7 via Smad2/4 in Human Renal Proximal Tubular Epithelial Cells
por: Watanabe, Jun, et al.
Publicado: (2016)

Impact of olmesartan on blood pressure, endothelial function, and cardiovascular outcomes
por: Pimenta, Eduardo, et al.
Publicado: (2010)

Association Between Urinary Type IV Collagen Level and Deterioration of Renal Function in Type 2 Diabetic Patients Without Overt Proteinuria
por: Araki, Shin-ichi, et al.
Publicado: (2010)

Role of elevated serum uric acid levels at the onset of overt nephropathy in the risk for renal function decline in patients with type 2 diabetes
por: Tanaka, Kentaro, et al.
Publicado: (2015)

Overt Diabetes in Pregnancy
por: Goyal, Alpesh, et al.
Publicado: (2022)

Curcumin as a major active component of turmeric attenuates proteinuria in patients with overt diabetic nephropathy
por: Vanaie, Azam, et al.
Publicado: (2019)

Effects of olmesartan on arterial stiffness in rats with chronic renal failure
por: Chuang, Yao-Chen, et al.
Publicado: (2012)

Enteropathy Associated with Olmesartan
por: Silva, Bruno Moreira da, et al.
Publicado: (2015)

Difference in the effects of switching from Candesartan to Olmesartan or Telmisartan to Olmesartan in hypertensive patients with type 2 diabetes: the COTO study
por: Daikuhara, Hiroyuki, et al.
Publicado: (2014)

Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study
por: Ritz, E., et al.
Publicado: (2009)

Abnormal Angiogenesis in Diabetic Nephropathy
por: Nakagawa, Takahiko, et al.
Publicado: (2009)

Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study
por: Bichu, Prasad, et al.
Publicado: (2009)

Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study
por: Martinez-Martin, F J, et al.
Publicado: (2011)

Correction to: Overt Diabetes in Pregnancy
por: Goyal, Alpesh, et al.
Publicado: (2022)

A new Classification of Diabetic Nephropathy 2014: a report from Joint Committee on Diabetic Nephropathy
por: Haneda, Masakazu, et al.
Publicado: (2015)

Olmesartan: Induced maculopapular rash
por: Bhushan, Aruna, et al.
Publicado: (2013)

Enteropatía secundaria a olmesartán
por: Curieses Luengo, María, et al.
Publicado: (2017)

Olmesartan is More Effective Than Other Angiotensin Receptor Antagonists in Reducing Proteinuria in Patients With Chronic Kidney Disease Other Than Diabetic Nephropathy()
por: Ono, Takashi, et al.
Publicado: (2013)

Severe spruelike enteropathy and collagenous colitis caused by olmesartan
por: Kaneko, Shiho, et al.
Publicado: (2021)

Association of Sympathovagal Imbalance with Cardiovascular Risks in Overt Hypothyroidism
por: Syamsunder, Avupati Naga, et al.
Publicado: (2013)

Risk factors associated with the development of overt nephropathy in type 2 diabetes patients: A 12 years observational study
por: Viswanathan, Vijay, et al.
Publicado: (2012)

Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy
por: Gale, Jeremy D., et al.
Publicado: (2018)

Microinflammation in the pathogenesis of diabetic nephropathy
por: Shikata, Kenichi, et al.
Publicado: (2013)

Predictive Effects of Urinary Liver-Type Fatty Acid–Binding Protein for Deteriorating Renal Function and Incidence of Cardiovascular Disease in Type 2 Diabetic Patients Without Advanced Nephropathy
por: Araki, Shin-ichi, et al.
Publicado: (2013)

The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) Observational Follow‐Up Study: Benefits of RAS Blockade With Olmesartan Treatment Are Sustained After Study Discontinuation
por: Menne, Jan, et al.
Publicado: (2014)

Relationship between achieved blood pressure, dietary habits and cardiovascular disease in hypertensive patients treated with olmesartan: the OMEGA study
por: Teramoto, Tamio, et al.
Publicado: (2012)

Relationship between achieved blood pressure, dietary habits and cardiovascular disease in hypertensive patients treated with olmesartan: the OMEGA study
por: Teramoto, Tamio, et al.
Publicado: (2012)

Olmesartan medoxomil reverses glomerulosclerosis in renal tissue induced by myocardial infarction without changes in renal function
por: LU, XIAO-MEI, et al.
Publicado: (2014)

Olmesartan-Induced Sprue Like Enteropathy
por: Carneiro, Liliana, et al.
Publicado: (2016)

Rare Case of Olmesartan Induced Enteropathy
por: Handa, Richa, et al.
Publicado: (2017)

Association between erectile dysfunction and cardiovascular risk in individuals with type-2 diabetes without overt cardiovascular disease
por: Meena, Babu Lal, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ivcd1a6ob539ij60o4sq7kfpcr